e-therapeutics plc

AIM:ETX 주식 보고서

시가총액: UK£52.6m

e-therapeutics 과거 수익 실적

과거 기준 확인 0/6

e-therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 22% per year.

주요 정보

-25.6%

수익 성장률

-6.4%

EPS 성장률

Biotechs 산업 성장11.5%
매출 성장률22.0%
자기자본 수익률-36.5%
순이익-2,957.6%
최근 수익 업데이트31 Jul 2023

최근 과거 실적 업데이트

Recent updates

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Jan 05
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Sep 13
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Mar 27
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Jul 07
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Oct 28
We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

Mar 21
Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Feb 14
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Jan 10
Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

Dec 06
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

수익 및 비용 분석

e-therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

AIM:ETX 수익, 비용 및 수입 (GBP Millions )
날짜수익수익G+A 비용R&D 비용
31 Jul 230-1049
30 Apr 230-948
31 Jan 230-837
31 Oct 220-947
31 Jul 220-947
30 Apr 220-946
31 Jan 220-846
31 Oct 211-635
31 Jul 211-424
30 Apr 211-423
31 Jan 210-423
31 Oct 200-422
31 Jul 200-322
30 Apr 200-322
31 Jan 200-212
31 Oct 190-312
31 Jul 190-313
30 Apr 190-413
31 Jan 190-414
31 Oct 180-424
31 Jul 180-524
30 Apr 180-525
31 Jan 180-525
31 Oct 170-726
31 Jul 170-827
30 Apr 170-1129
31 Jan 170-13211
31 Oct 160-13211
31 Jul 160-12211
30 Apr 160-11211
31 Jan 160-9210
31 Oct 150-8210
31 Jul 150-829
30 Apr 150-829
31 Jan 150-829
31 Oct 140-728
31 Jul 140-727
30 Apr 140-626
31 Jan 140-515
31 Oct 130-515

양질의 수익: ETX is currently unprofitable.

이익 마진 증가: ETX is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: ETX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

성장 가속화: Unable to compare ETX's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: ETX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).


자기자본 수익률

높은 ROE: ETX has a negative Return on Equity (-36.53%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기